Impact of Grade, Hormone Receptor, and HER-2 Status in Women with Breast Cancer on Response to Specific Chemotherapeutic Agents by in vitro Adenosine Triphosphate-based Chemotherapy Response Assay
Journal of Korean Medical Science
;
: 1150-1157, 2009.
Article
in English
| WPRIM
| ID: wpr-203375
ABSTRACT
This study was designed to assess whether histological and biological factors of breast cancer can predict chemoresponse to specific agents. Adenosine triphosphate-based chemotherapy response assay (ATP-CRA) was employed to retrieve chemoresponse to 5-fluorouracil (5-FU), doxetaxel, doxorubicin, epirubicin, and paclitaxel in 49 patients. Tumors with high histologic and nuclear grade have higher response rate to doxorubicin (P<0.05) and palitaxel (P<0.05). Estrogen receptor (ER)-negative tumors respond well to doxorubicin (P=0.038), and progesterone receptor (PR)-negative tumors to 5-FU (P=0.039), doxetaxel (P=0.038), doxorubicin (P=0.000), epirubicin (P=0.010), and paclitaxel (P=0.003). Among the breast cancer subtypes determined by ER, PR, and HER-2 immunohistochemical stains, the HER-2+/ER- subtype has a higher response rate to doxorubicin (P=0.008). This in vitro result suggests that the combination of histologic and nuclear grade, hormone receptor, and HER-2 status can be a predictive factor of response to specific chemotherapy agents. Further in vivo study should be followed for clinical trials.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Breast Neoplasms
/
Drug Screening Assays, Antitumor
/
Epirubicin
/
Doxorubicin
/
Receptors, Progesterone
/
Receptors, Estrogen
/
Adenosine Triphosphate
/
Paclitaxel
/
Receptor, ErbB-2
/
Fluorouracil
Limits:
Adult
/
Aged
/
Female
/
Humans
Language:
English
Journal:
Journal of Korean Medical Science
Year:
2009
Type:
Article
Similar
MEDLINE
...
LILACS
LIS